RedHill advancing study of opaganib in COVID-19 with two new trial applications

RedHill Biopharma Ltd. (RDHL -0.7%) has submitted applications in the UK and Italy for its Phase 2/3 clinical trial evaluating Yeliva (opaganib) on top of standard-of-care treatment in hospitalized patients with severe COVID-19 pneumonia who are receiving supplemental oxygen.

Up to 40 sites across a range of countries will be recruited for the study.

The primary endpoint will be the proportion of patients requiring mechanical ventilation by day 14 compared to those receiving standard-of-care therapy alone. Preliminary data should be available when ~100 participants have been evaluated for the primary objective.

Last week, it filed an application in Russia for the study.

Opaganib inhibits an enzyme called sphingosine kinase-2 (SK2) which blocks the synthesis of a lipid-signaling molecule called sphingosine 1-phosphate (S1P) that promotes cancer cell growth and pathological inflammation.

https://seekingalpha.com/news/3584270-redhill-advancing-study-of-opaganib-in-covidminus-19-two-new-trial-applications